Get Started
To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.
Get in Touch
Overview
• 95% cell transfection efficiency
• No observed cytotoxicity
• Gene knockdown via siRNA expression
• in vitro and in vivo applications
• Non-viral transfection
Applications:
• siRNA transfection for gene knockdown via RNAi both in vitro and in vivo
Top Right: Enriched (>90%) E18 primary rat cortical neurons treated at DIV12 with Neuro9 siRNA against HPRT. HPRT mRNA assayed by qPCR 48h post-treatment. *** P < 0.001
Middle Right: Enriched (>90%) E18 primary rat cortical neurons treated at DIV7 with Neuro9 siRNA against HPRT for 48 hours. Cell viability assayed using PrestoBlue.
Bottom Right: Primary rat neurons were treated at various stages of maturity with Neuro9 siRNA against PTEN. Neuro9 is well tolerated and can be applied at DIV ≥ 2. This flexibility opens doors to new experimental possibilities. *** P < 0.001
90% knockdown in 95% of Cells
No Observable Toxicity
Mediate Gene Expression as Early as DIV2
Neuro9 in vitro cell culture and transfection
siRNA : > 95% Cellular Transfection Efficiency
Images: Fluorescently labeled Neuro9 (red) is used to observe uptake by MAP2+ neurons (green).
Plot: Flow cytometry indicates Neuro9 uptake in >95% of cells
Neuro9 in vivo
siRNA : > 95% Transfection Efficiency
Neuro9 (red) was locally injected into rat somatosensory cortex. Brains were removed 5 days later, sliced and imaged. Calcein-AM dye (green) indicates
neurons were alive when imaged. Western blots from samples 1mm from the injection site exhibit significant knockdown of target gene PTEN compared to “control” samples taken from the opposite hemisphere and samples treated with Luc siRNA.
Neuro9 Spark
Transfection Kits
Transfection Kits
| Kit Type | Encapsulates | Treats (wells of 24 well plate) | |
| siRNA | 2 nmol (2x) | 50 | NWS0001 |
| siRNA | 5 nmol | 100 | NWS0002 |
Neuro9 Ignite
Transfection Kits
Transfection Kits
| Kit Type | Encapsulates | Treats (wells of 24 well plate) | |
| siRNA | 0.5 mg | 15 | NWT0001 |
| siRNA | 2 mg | 20 | NWT0002 |
Resource Center
Publication - Abstract
July 01, 2020
Journal of Controlled Release
Publication - Abstract
May 08, 2020
Vaccines
Publication - Abstract
April 02, 2020
Journal of Controlled Release
Publication - Abstract
December 31, 2019
Vaccines
Publication - Abstract
May 31, 2019
Vaccine
Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.